查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1805868

長效 PEG-rhG-CSF 市場報告：趨勢、預測和競爭分析（至 2031 年）

Long-acting PEG-rhG-CSF Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球長效聚乙二醇重組人類粒細胞集落刺激因子 (PEG-rhG-CSF) 市場前景廣闊，在腫瘤和血液疾病領域蘊藏著機會。預計2025年至2031年期間，全球長效聚乙二醇重組人類粒細胞集落刺激因子 (PEG-rhG-CSF) 市場的複合年成長率將達到6.8%。該市場的主要促進因素包括癌症發病率的上升、對長效生技藥品的偏好日益成長以及生物相似藥供應的日益充足。

  • Lucintel 預測仿製學名藥將在預測期內經歷最高的成長率。
  • 從應用來看，腫瘤學預計將實現高速成長。
  • 依地區分類，預計亞太地區將在預測期內實現最高成長。

長效PEG-rhG-CSF市場的新趨勢

長效 PEG-rhG-CSF 市場受到許多重要趨勢的影響，這些趨勢反映了生物製藥、衛生經濟學和以患者為中心的癌症治療策略的範式變化。

  • 生物相似藥的主導地位和價格侵蝕：最強勁的趨勢是Pegfilgrastim生物相似藥市場佔有率的不斷成長。隨著更多生物相似藥進入市場並在全球範圍內核准，價格競爭將加劇，這可能會為醫療保健系統帶來顯著的成本節約，並擴大患者獲得這種重要支持性治療藥物的管道。
  • 注重患者便利性和自主給藥：開發和使用患者友善的Pegfilgrastim給藥系統正日益成為趨勢。安全性更高的自動注射器系統和預填充式注射器正日益普及，它們為患者提供了便利，最大限度地減少了就診次數，並可能提高患者對治療方法的依從性，尤其是在門診環境中。
  • 強調展示價值和成本效益：隨著醫療保健成本的上升，展示長效 PEG-rhG-CSF 的成本效益和價值至關重要，尤其是相對於短效 G-CSF 以及治療化療嗜中性白血球低下症細胞減少症和相關併發症（例如嗜中性白血球低下症和住院治療）的成本而言。
  • 個體化給藥方案：近期證據表明，統一劑量的Pegfilgrastim可能並非對每個人都適用。目前，人們正在探索個人化給藥方案，根據患者特異性參數（例如體重、體表面積和個體化療方案）進行調整，以最大程度提高療效並最大程度減少副作用。
  • 融入整體癌症護理途徑：長效 PEG-rhG-CSF 擴大被納入整體癌症護理途徑和治療建議中，以提供適當和及時的預防化療嗜中性白血球低下症，從而改善癌症患者的整體管理和結果。

這些趨勢正在改變長效 PEG-rhG-CSF 市場，透過生物相似藥競爭降低價格，透過新穎的給藥方式提高患者的便利性，強調治療的經濟價值，探索更個人化的治療策略，並無縫整合到常規癌症護理實踐中。

長效PEG-rhG-CSF市場的最新趨勢

長效 PEG-rhG-CSF 市場正在經歷一系列重要的新興市場發展，突顯了其持續轉型及其對支持性癌症治療的影響。

  • 多種生物相似藥產品的成功商業化和開發：一項關鍵的發展是在主要醫藥市場開發、監管部門核准和推出幾種聚乙二醇非Pegfilgrastim的生物學名藥製劑，為原創品牌提供了強大的競爭，並成為降價的主要推動力。
  • 醫療保健專業人員繼續接受和採用生物相似藥：Pegfilgrastim生物相似藥具有與參考產品相似的功效和安全性，從而提高了醫療保健專業人員開具處方時的熟悉度和舒適度，並鼓勵提高生物學名藥的市場滲透率。
  • 提升患者便利性的藥物傳遞創新：製藥公司致力於開發和引入方便用戶使用的Pegfilgrastim藥物輸送技術，例如帶有安全裝置的預填充式注射器注射器和自動注射筆。這些創新旨在簡化給藥並改善患者體驗。
  • 越來越多的現實世界證據支持使用生物相似藥：越來越多的現實世界證據證Pegfilgrastim生物相似藥在日常臨床實踐中的有效性和安全性，這增加了處方者和患者的信心。
  • 專利到期和生物相似藥進入市場：關鍵Pegfilgrastim製劑的專利到期可能為新的生物相似藥進入市場打開大門，從而加劇市場競爭並可能降低價格。

這些進步正在影響長效 PEG-rhG-CSF 市場，透過提高生物相似藥的價格和可用性、透過先進的輸送系統為患者提供便捷的給藥方式、關於生物相似藥安全性和有效性的堅實依證以及增加的市場競爭。

目錄

第1章執行摘要

第2章 市場概述

  • 背景和分類
  • 供應鏈

第3章：市場趨勢與預測分析

  • 宏觀經濟趨勢與預測
  • 產業驅動力與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

4. 全球長效 PEG-rhG-CSF 市場（依類型）

  • 概述
  • 吸引力分析：依類型
  • 創新藥物：趨勢與預測（2019-2031）
  • 學名藥：趨勢與預測（2019-2031）

5. 全球長效 PEG-rhG-CSF 市場（依應用）

  • 概述
  • 吸引力分析：依用途
  • 腫瘤學：趨勢與預測（2019-2031）
  • 血液系統疾病：趨勢與預測（2019-2031）
  • 其他：趨勢與預測（2019-2031）

第6章區域分析

  • 概述
  • 全球長效 PEG-rhG-CSF 市場（依區域）

7. 北美長效PEG-rhG-CSF市場

  • 概述
  • 北美長效 PEG-rhG-CSF 市場（依類型）
  • 北美長效PEG-rhG-CSF市場（依應用）
  • 美國長效PEG-rhG-CSF市場
  • 墨西哥長效PEG-rhG-CSF市場
  • 加拿大長效PEG-rhG-CSF市場

8. 歐洲長效PEG-rhG-CSF市場

  • 概述
  • 歐洲長效PEG-rhG-CSF市場類型
  • 歐洲長效PEG-rhG-CSF市場（依應用）
  • 德國長效PEG-rhG-CSF市場
  • 法國長效PEG-rhG-CSF市場
  • 西班牙長效PEG-rhG-CSF市場
  • 義大利長效PEG-rhG-CSF市場
  • 英國長效PEG-rhG-CSF市場

9. 亞太地區長效 PEG-rhG-CSF 市場

  • 概述
  • 亞太長效PEG-rhG-CSF市場（依類型）
  • 亞太長效PEG-rhG-CSF市場（依應用）
  • 日本長效PEG-rhG-CSF市場
  • 印度長效 PEG-rhG-CSF 市場
  • 中國長效PEG-rhG-CSF市場
  • 韓國長效PEG-rhG-CSF市場
  • 印尼長效PEG-rhG-CSF市場

10. 世界其他地區（ROW）長效PEG-rhG-CSF市場

  • 概述
  • 世界其他地區（ROW）長效 PEG-rhG-CSF 市場（依類型）
  • 世界其他地區（ROW）長效 PEG-rhG-CSF 市場（依應用）
  • 中東長效PEG-rhG-CSF市場
  • 南美洲長效PEG-rhG-CSF市場
  • 非洲長效PEG-rhG-CSF市場

第11章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析
    • 競爭對手之間的競爭
    • 買方議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 新進入者的威脅
  • 市場佔有率分析

第12章機會與策略分析

  • 價值鏈分析
  • 成長機會分析
    • 依類型分類的成長機會
    • 依應用分類的成長機會
  • 全球長效 PEG-rhG-CSF 市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 認證和許可
    • 企業合併（M&A）、協議、合作與合資企業

第13章 價值鏈主要企業概況

  • 競爭分析
  • Amgen
  • Pfizer
  • Mylan
  • Sandoz
  • Biocon Biologics
  • Coherus BioSciences
  • Fresenius Kabi
  • CSPC
  • Qilu Pharmaceutical
  • Jiangsu Hengrui Medicine

第14章 附錄

  • 圖片列表
  • 表格列表
  • 分析方法
  • 免責聲明
  • 版權
  • 簡稱和技術單位
  • 關於 Lucintel
  • 詢問

The future of the global long-acting PEG-rhG-CSF market looks promising with opportunities in the neoplastic disease and blood disorder markets. The global long-acting PEG-rhG-CSF market is expected to grow with a CAGR of 6.8% from 2025 to 2031. The major drivers for this market are the rising prevalence of cancer, the growing preference for long-acting biologics, and the increasing availability of biosimilars.

  • Lucintel forecasts that, within the type category, generic drugs are expected to witness higher growth over the forecast period.
  • Within the application category, neoplastic disease is expected to witness higher growth.
  • In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Long-acting PEG-rhG-CSF Market

The Long-acting PEG-rhG-CSF market is under the impact of a number of important trends that mirror changing paradigms in biopharmaceuticals, healthcare economics, and patient-centered treatment strategies in oncology.

  • Biosimilar Domination and Price Erosion: The strongest trend is the growing market share gain experienced by biosimilar versions of pegfilgrastim. With additional biosimilars entering the market and securing regulatory approval across the world, price competition will strengthen, causing substantial cost savings to healthcare systems and possibly expanding patient access to this critical supportive care drug.
  • Focus on Patient Convenience and Self-Administration: There is an increasing trend towards the creation and use of patient-convenient administration systems for pegfilgrastim. Auto-injector systems and pre-filled syringes with improved safety features are becoming increasingly popular, providing patients with more convenience, minimizing the frequency of clinic visits, and potentially enhancing compliance with the treatment regimen, especially in the outpatient environment.
  • Emphasis on Value and Cost-Effectiveness Demonstration: As costs of healthcare rise, there is great stress on proving the cost-effectiveness and value of Long-acting PEG-rhG-CSF, particularly in relation to shorter-acting G-CSFs and the expense of treating chemotherapy-induced neutropenia and related complications, e.g., febrile neutropenia and hospitalization.
  • Personalized Dosing Approaches: Recent evidence is highlighting that one uniform dose of pegfilgrastim might not be the best for everyone. There is a move towards researching individualized dosing approaches by using patient-specific parameters such as body weight, body surface area, and individual chemotherapy regimens in an effort to maximize efficiency and minimize side effects.
  • Integration into Overall Cancer Care Pathways: Long-acting PEG-rhG-CSF is being increasingly integrated into overall cancer care pathways and treatment recommendations so that appropriate and timely prophylaxis against chemotherapy-induced neutropenia is provided, leading to improved overall management of and outcomes in patients with cancer.

These trends are transforming the Long-acting PEG-rhG-CSF market by reducing prices through biosimilar competition, improving patient convenience with newer delivery approaches, highlighting the economic value of the therapy, looking at more individualized treatment strategies, and integrating it seamlessly into routine cancer care practices.

Recent Developments in the Long-acting PEG-rhG-CSF Market

The Long-acting PEG-rhG-CSF market has seen a number of critical developments that highlight its continued transformation and influence on supportive cancer care.

  • Successful Commercialization and Development of Several Biosimilar Products: One of the major developments is that several biosimilar versions of pegfilgrastim have been successfully developed, approved by the regulatory authorities, and launched across key pharma markets. This has brought immense competition to the originator brand and has been a primary driver of price cuts.
  • Sustained Acceptance and Uptake of Biosimilars by Healthcare Professionals: With time, healthcare professionals have grown more accustomed and comfortable prescribing pegfilgrastim biosimilars, aware of their similar efficacy and safety profiles with the reference product. Sustained acceptance has promoted enhanced market penetration of biosimilars.
  • Innovation in Drug Delivery Technologies for Patient Convenience: Pharmaceutical companies have focused on developing and implementing user-friendly drug delivery technologies for pegfilgrastim, such as pre-filled syringes with safety mechanisms and auto-injector pens. These innovations aim to simplify administration and improve the patient experience.
  • Increasing Body of Real-World Evidence in Support of Use of Biosimilars: More real-world evidence studies are being reported documenting the efficacy and safety of pegfilgrastim biosimilars in everyday clinical practice, continuing to build prescriber and patient confidence.
  • Repeated Expiration of Patents and New Biosimilar Players: Continued expiration of patents on important pegfilgrastim products continues to open the doors for new biosimilar players to come into the market, adding more competition and possibly pushing prices lower.

These advances are affecting the Long-acting PEG-rhG-CSF market by making it more affordable and accessible using biosimilars, making administration easier for patients with advanced delivery systems, establishing a robust evidence base for biosimilar safety and efficacy, and creating a more competitive market setting.

Strategic Growth Opportunities in the Long-acting PEG-rhG-CSF Market

The Long-acting PEG-rhG-CSF market, although mainly developed for the prevention of chemotherapy-induced neutropenia, has a number of strategic growth opportunities across key applications in oncology and hematology.

  • Increasing Prophylactic Application in Moderate-Risk Chemotherapy Regimens: Pegfilgrastim is usually recommended by current guidelines for high-risk regimens. An emerging opportunity exists with the identification and expansion of its prophylactic application in certain moderate-risk regimens where the cost may be offset by the benefit of avoiding neutropenic complications, especially given the availability of biosimilars at lower costs.
  • Tapering Dosing Strategies in Special Patient Populations: Studies on patient-specific dosing based on various factors like body weight, age, and comorbidities can result in more effective and cost-conscious utilization of pegfilgrastim among such patient groups, offering a future growth opportunity through resource optimization.
  • Investigating Use with Next-Generation Cancer Therapies: With each new myelosuppressive cancer therapy introduced, such as targeted therapies and immunotherapies, integrated into treatment combinations, there might be an escalating demand for prophylactic pegfilgrastim to alleviate related neutropenia, constituting a strategic growth opportunity.
  • Growing Adoption in Emerging Economies with Value Biosimilars: Availability of lower-priced biosimilar equivalents of pegfilgrastim presents a big growth opportunity to increase access to this critical supportive care in emerging economies where price can be an important obstacle to treatment. Distribution networks and partnership strategies will play a key role.
  • Examining Use in Hematopoietic Stem Cell Transplant: Although mostly utilized in chemotherapy-induced neutropenia, the potential use of pegfilgrastim in hematopoietic stem cell mobilization can be studied further and optimized and may widen its use in transplantation.

Profiting from such strategic expansion opportunities demands constant clinical research to streamline treatment protocols and determine new uses, manufacturing specific dosing strategies and preparations, as well as successful market access tactics, especially for biosimilars in underdeveloped areas.

Long-acting PEG-rhG-CSF Market Driver and Challenges

The Long-acting PEG-rhG-CSF market is affected by an intricate interrelationship of drivers and challenges emanating from clinical demand, technological development, economic pressures, and regulatory frameworks controlling biopharmaceuticals.

The factors responsible for driving the long-acting PEG-rhG-CSF market include:

1. Established efficacy in prevention of chemotherapy-induced neutropenia: The strong clinical evidence that proves the efficacy of pegfilgrastim in the prevention of the incidence and severity of neutropenia continues to be the major reason for its application in patients undergoing myelosuppressive chemotherapy.

2. Growing global prevalence of cancer and chemotherapy use: The increasing global cancer burden and the persistent use of chemotherapy as an important treatment strategy guarantee an ongoing demand for supportive treatments such as pegfilgrastim.

3. Increasing availability and acceptance of biosimilars: Increased numbers of approved and commercially available pegfilgrastim biosimilars offer lower-cost treatment alternatives, increasing market access and overall market volume.

4. Convenience and friendly patient delivery device development: The availability and usage of auto-injectors increase patient convenience and compliance, further enhancing pegfilgrastim usage, especially among outpatients.

5. Reimbursement policy and supportive clinical practice guidelines: Favorable reimbursement policies in most healthcare systems and recommendations of oncology organizations allow the utilization of pegfilgrastim in suitable clinical practice settings.

Challenges in the long-acting PEG-rhG-CSF market are:

1. Increasing price competition from biosimilars: The rise in the number of biosimilar entrants creates huge price erosion, affecting the profitability and revenues of both biosimilar and originator manufacturers.

2. Optimal patient selection and personalized dosing: Who to treat and how much pegfilgrastim to give them remain subjects for ongoing investigation and optimization.

3. Coping with the cost burden on healthcare systems: Even in the presence of biosimilars, overall supportive cancer care costs, including pegfilgrastim, continue to pose a challenge for healthcare payers and systems around the world.

In summary, the Long-acting PEG-rhG-CSF market is fueled by its proven efficacy, the mounting demand for neutropenia treatment because of the rising burden of cancer globally, the availability of cheaper biosimilars, and improved delivery device advancements. Nevertheless, the market is challenged by heightening price competition, the demand for individually customized treatment strategies, and the sheer cost burden on healthcare systems.

List of Long-acting PEG-rhG-CSF Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leveraging integration opportunities across the value chain. With these strategies, long-acting PEG-rhG-CSF companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the long-acting PEG-rhG-CSF companies profiled in this report include:

  • Amgen
  • Pfizer
  • Mylan
  • Sandoz
  • Biocon Biologics
  • Coherus BioSciences
  • Fresenius Kabi
  • CSPC
  • Qilu Pharmaceutical
  • Jiangsu Hengrui Medicine

Long-acting PEG-rhG-CSF Market by Segment

The study includes a forecast for the global long-acting PEG-rhG-CSF market by type, application, and region.

Long-acting PEG-rhG-CSF Market by Type [Value from 2019 to 2031]:

  • Innovative Drugs
  • Generic Drugs

Long-acting PEG-rhG-CSF Market by Application [Value from 2019 to 2031]:

  • Neoplastic Diseases
  • Blood Disorders
  • Others

Long-acting PEG-rhG-CSF Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Long-acting PEG-rhG-CSF Market

The Long-acting PEG-rhG-CSF market, a cornerstone of supportive cancer care, continues to evolve with a strong emphasis on biosimilar competition and enhanced patient convenience. Designed to reduce the incidence of chemotherapy-induced neutropenia with less frequent dosing than short-acting G-CSFs, pegfilgrastim has become a standard of care. Recent developments are characterized by the increasing availability and uptake of biosimilar versions, driving price adjustments and expanding patient access globally. Delivery device innovations, including pre-filled syringes and auto-injectors, are also significantly contributing to defining market trends in various regions.

  • United States: Significant biosimilar erosion has occurred within the US Long-acting PEG-rhG-CSF market, driving considerable cost savings for patients and healthcare providers alike. Recent changes have involved the ongoing introduction of new biosimilars, as well as fierce price wars between manufacturers. The emphasis lies in balancing affordability with maintaining a consistent level of access to this critical supportive treatment for patients on myelosuppressive chemotherapy.
  • China: China's market for Long-acting PEG-rhG-CSF is experiencing swift growth, fueled by an expanding cancer patient base and rising uptake of sophisticated cancer therapies. Developments in the recent past include the approval and launch of multiple locally manufactured pegfilgrastim biosimilars. The biosimilars are reducing the cost of therapy and making it more accessible, driving strong market growth and greater competition with the reference product.
  • Germany: The German healthcare system has easily adopted biosimilar forms of Long-acting PEG-rhG-CSF, leading to significant cost savings. Recent advancements include a high level of biosimilar prescribing, fueled by positive reimbursement policies and physician acceptance. The market focuses on guaranteeing the quality and effectiveness of biosimilars while maximizing healthcare spending for supportive cancer care.
  • India: Long-acting PEG-rhG-CSF in India is marked by rising affordability and accessibility, which is mainly attributed to the availability of a number of local biosimilar producers. Recent trends encompass greater usage of these economic alternatives in both public and private sectors. Measures are being taken to implement strict quality control and increase access across the nation.
  • Japan: Japan's market for Long-acting PEG-rhG-CSF is witnessing a slow but consistent rise in the adoption of biosimilars. Recent events include cautious assessment of the safety and performance of biosimilar products by regulators and healthcare professionals. Although the rate of adoption is relatively conservative, cost-containment pressures are likely to propel more biosimilar penetration in the next few years.

Features of the Global Long-acting PEG-rhG-CSF Market

  • Market Size Estimates: Long-acting PEG-rhG-CSF market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Long-acting PEG-rhG-CSF market size by type, application, and region in terms of value ($B).
  • Regional Analysis: Long-acting PEG-rhG-CSF market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the long-acting PEG-rhG-CSF market.
  • Strategic Analysis: This includes M&A, new product development, and the competitive landscape of the long-acting PEG-rhG-CSF market.

Analysis of the competitive intensity of the industry based on Porter's Five Forces model.

This report answers the following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the long-acting PEG-rhG-CSF market by type (innovative drugs and generic drugs), application (neoplastic diseases, blood disorders, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Long-acting PEG-rhG-CSF Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Innovative Drugs: Trends and Forecast (2019-2031)
  • 4.4 Generic Drugs: Trends and Forecast (2019-2031)

5. Global Long-acting PEG-rhG-CSF Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Neoplastic Diseases: Trends and Forecast (2019-2031)
  • 5.4 Blood Disorders: Trends and Forecast (2019-2031)
  • 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Long-acting PEG-rhG-CSF Market by Region

7. North American Long-acting PEG-rhG-CSF Market

  • 7.1 Overview
  • 7.2 North American Long-acting PEG-rhG-CSF Market by Type
  • 7.3 North American Long-acting PEG-rhG-CSF Market by Application
  • 7.4 United States Long-acting PEG-rhG-CSF Market
  • 7.5 Mexican Long-acting PEG-rhG-CSF Market
  • 7.6 Canadian Long-acting PEG-rhG-CSF Market

8. European Long-acting PEG-rhG-CSF Market

  • 8.1 Overview
  • 8.2 European Long-acting PEG-rhG-CSF Market by Type
  • 8.3 European Long-acting PEG-rhG-CSF Market by Application
  • 8.4 German Long-acting PEG-rhG-CSF Market
  • 8.5 French Long-acting PEG-rhG-CSF Market
  • 8.6 Spanish Long-acting PEG-rhG-CSF Market
  • 8.7 Italian Long-acting PEG-rhG-CSF Market
  • 8.8 United Kingdom Long-acting PEG-rhG-CSF Market

9. APAC Long-acting PEG-rhG-CSF Market

  • 9.1 Overview
  • 9.2 APAC Long-acting PEG-rhG-CSF Market by Type
  • 9.3 APAC Long-acting PEG-rhG-CSF Market by Application
  • 9.4 Japanese Long-acting PEG-rhG-CSF Market
  • 9.5 Indian Long-acting PEG-rhG-CSF Market
  • 9.6 Chinese Long-acting PEG-rhG-CSF Market
  • 9.7 South Korean Long-acting PEG-rhG-CSF Market
  • 9.8 Indonesian Long-acting PEG-rhG-CSF Market

10. ROW Long-acting PEG-rhG-CSF Market

  • 10.1 Overview
  • 10.2 ROW Long-acting PEG-rhG-CSF Market by Type
  • 10.3 ROW Long-acting PEG-rhG-CSF Market by Application
  • 10.4 Middle Eastern Long-acting PEG-rhG-CSF Market
  • 10.5 South American Long-acting PEG-rhG-CSF Market
  • 10.6 African Long-acting PEG-rhG-CSF Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Application
  • 12.3 Emerging Trends in the Global Long-acting PEG-rhG-CSF Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 Amgen
    • Company Overview
    • Long-acting PEG-rhG-CSF Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Pfizer
    • Company Overview
    • Long-acting PEG-rhG-CSF Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Mylan
    • Company Overview
    • Long-acting PEG-rhG-CSF Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Sandoz
    • Company Overview
    • Long-acting PEG-rhG-CSF Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Biocon Biologics
    • Company Overview
    • Long-acting PEG-rhG-CSF Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.7 Coherus BioSciences
    • Company Overview
    • Long-acting PEG-rhG-CSF Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.8 Fresenius Kabi
    • Company Overview
    • Long-acting PEG-rhG-CSF Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.9 CSPC
    • Company Overview
    • Long-acting PEG-rhG-CSF Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.10 Qilu Pharmaceutical
    • Company Overview
    • Long-acting PEG-rhG-CSF Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.11 Jiangsu Hengrui Medicine
    • Company Overview
    • Long-acting PEG-rhG-CSF Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Long-acting PEG-rhG-CSF Market
  • Figure 2.1: Usage of Long-acting PEG-rhG-CSF Market
  • Figure 2.2: Classification of the Global Long-acting PEG-rhG-CSF Market
  • Figure 2.3: Supply Chain of the Global Long-acting PEG-rhG-CSF Market
  • Figure 2.4: Driver and Challenges of the Long-acting PEG-rhG-CSF Market
  • Figure 3.1: Trends of the Global GDP Growth Rate
  • Figure 3.2: Trends of the Global Population Growth Rate
  • Figure 3.3: Trends of the Global Inflation Rate
  • Figure 3.4: Trends of the Global Unemployment Rate
  • Figure 3.5: Trends of the Regional GDP Growth Rate
  • Figure 3.6: Trends of the Regional Population Growth Rate
  • Figure 3.7: Trends of the Regional Inflation Rate
  • Figure 3.8: Trends of the Regional Unemployment Rate
  • Figure 3.9: Trends of Regional Per Capita Income
  • Figure 3.10: Forecast for the Global GDP Growth Rate
  • Figure 3.11: Forecast for the Global Population Growth Rate
  • Figure 3.12: Forecast for the Global Inflation Rate
  • Figure 3.13: Forecast for the Global Unemployment Rate
  • Figure 3.14: Forecast for the Regional GDP Growth Rate
  • Figure 3.15: Forecast for the Regional Population Growth Rate
  • Figure 3.16: Forecast for the Regional Inflation Rate
  • Figure 3.17: Forecast for the Regional Unemployment Rate
  • Figure 3.18: Forecast for Regional Per Capita Income
  • Figure 4.1: Global Long-acting PEG-rhG-CSF Market by Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global Long-acting PEG-rhG-CSF Market ($B) by Type
  • Figure 4.3: Forecast for the Global Long-acting PEG-rhG-CSF Market ($B) by Type
  • Figure 4.4: Trends and Forecast for Innovative Drugs in the Global Long-acting PEG-rhG-CSF Market (2019-2031)
  • Figure 4.5: Trends and Forecast for Generic Drugs in the Global Long-acting PEG-rhG-CSF Market (2019-2031)
  • Figure 5.1: Global Long-acting PEG-rhG-CSF Market by Application in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global Long-acting PEG-rhG-CSF Market ($B) by Application
  • Figure 5.3: Forecast for the Global Long-acting PEG-rhG-CSF Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Neoplastic Diseases in the Global Long-acting PEG-rhG-CSF Market (2019-2031)
  • Figure 5.5: Trends and Forecast for Blood Disorders in the Global Long-acting PEG-rhG-CSF Market (2019-2031)
  • Figure 5.6: Trends and Forecast for Others in the Global Long-acting PEG-rhG-CSF Market (2019-2031)
  • Figure 6.1: Trends of the Global Long-acting PEG-rhG-CSF Market ($B) by Region (2019-2024)
  • Figure 6.2: Forecast for the Global Long-acting PEG-rhG-CSF Market ($B) by Region (2025-2031)
  • Figure 7.1: Trends and Forecast for the North American Long-acting PEG-rhG-CSF Market (2019-2031)
  • Figure 7.2: North American Long-acting PEG-rhG-CSF Market by Type in 2019, 2024, and 2031
  • Figure 7.3: Trends of the North American Long-acting PEG-rhG-CSF Market ($B) by Type (2019-2024)
  • Figure 7.4: Forecast for the North American Long-acting PEG-rhG-CSF Market ($B) by Type (2025-2031)
  • Figure 7.5: North American Long-acting PEG-rhG-CSF Market by Application in 2019, 2024, and 2031
  • Figure 7.6: Trends of the North American Long-acting PEG-rhG-CSF Market ($B) by Application (2019-2024)
  • Figure 7.7: Forecast for the North American Long-acting PEG-rhG-CSF Market ($B) by Application (2025-2031)
  • Figure 7.8: Trends and Forecast for the United States Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
  • Figure 7.9: Trends and Forecast for the Mexican Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
  • Figure 7.10: Trends and Forecast for the Canadian Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
  • Figure 8.1: Trends and Forecast for the European Long-acting PEG-rhG-CSF Market (2019-2031)
  • Figure 8.2: European Long-acting PEG-rhG-CSF Market by Type in 2019, 2024, and 2031
  • Figure 8.3: Trends of the European Long-acting PEG-rhG-CSF Market ($B) by Type (2019-2024)
  • Figure 8.4: Forecast for the European Long-acting PEG-rhG-CSF Market ($B) by Type (2025-2031)
  • Figure 8.5: European Long-acting PEG-rhG-CSF Market by Application in 2019, 2024, and 2031
  • Figure 8.6: Trends of the European Long-acting PEG-rhG-CSF Market ($B) by Application (2019-2024)
  • Figure 8.7: Forecast for the European Long-acting PEG-rhG-CSF Market ($B) by Application (2025-2031)
  • Figure 8.8: Trends and Forecast for the German Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the French Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
  • Figure 8.10: Trends and Forecast for the Spanish Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
  • Figure 8.11: Trends and Forecast for the Italian Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
  • Figure 8.12: Trends and Forecast for the United Kingdom Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
  • Figure 9.1: Trends and Forecast for the APAC Long-acting PEG-rhG-CSF Market (2019-2031)
  • Figure 9.2: APAC Long-acting PEG-rhG-CSF Market by Type in 2019, 2024, and 2031
  • Figure 9.3: Trends of the APAC Long-acting PEG-rhG-CSF Market ($B) by Type (2019-2024)
  • Figure 9.4: Forecast for the APAC Long-acting PEG-rhG-CSF Market ($B) by Type (2025-2031)
  • Figure 9.5: APAC Long-acting PEG-rhG-CSF Market by Application in 2019, 2024, and 2031
  • Figure 9.6: Trends of the APAC Long-acting PEG-rhG-CSF Market ($B) by Application (2019-2024)
  • Figure 9.7: Forecast for the APAC Long-acting PEG-rhG-CSF Market ($B) by Application (2025-2031)
  • Figure 9.8: Trends and Forecast for the Japanese Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Indian Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the Chinese Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the South Korean Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
  • Figure 9.12: Trends and Forecast for the Indonesian Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
  • Figure 10.1: Trends and Forecast for the ROW Long-acting PEG-rhG-CSF Market (2019-2031)
  • Figure 10.2: ROW Long-acting PEG-rhG-CSF Market by Type in 2019, 2024, and 2031
  • Figure 10.3: Trends of the ROW Long-acting PEG-rhG-CSF Market ($B) by Type (2019-2024)
  • Figure 10.4: Forecast for the ROW Long-acting PEG-rhG-CSF Market ($B) by Type (2025-2031)
  • Figure 10.5: ROW Long-acting PEG-rhG-CSF Market by Application in 2019, 2024, and 2031
  • Figure 10.6: Trends of the ROW Long-acting PEG-rhG-CSF Market ($B) by Application (2019-2024)
  • Figure 10.7: Forecast for the ROW Long-acting PEG-rhG-CSF Market ($B) by Application (2025-2031)
  • Figure 10.8: Trends and Forecast for the Middle Eastern Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the South American Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
  • Figure 10.10: Trends and Forecast for the African Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
  • Figure 11.1: Porter's Five Forces Analysis of the Global Long-acting PEG-rhG-CSF Market
  • Figure 11.2: Market Share (%) of Top Players in the Global Long-acting PEG-rhG-CSF Market (2024)
  • Figure 12.1: Growth Opportunities for the Global Long-acting PEG-rhG-CSF Market by Type
  • Figure 12.2: Growth Opportunities for the Global Long-acting PEG-rhG-CSF Market by Application
  • Figure 12.3: Growth Opportunities for the Global Long-acting PEG-rhG-CSF Market by Region
  • Figure 12.4: Emerging Trends in the Global Long-acting PEG-rhG-CSF Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Long-acting PEG-rhG-CSF Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the Long-acting PEG-rhG-CSF Market by Region
  • Table 1.3: Global Long-acting PEG-rhG-CSF Market Parameters and Attributes
  • Table 3.1: Trends of the Global Long-acting PEG-rhG-CSF Market (2019-2024)
  • Table 3.2: Forecast for the Global Long-acting PEG-rhG-CSF Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global Long-acting PEG-rhG-CSF Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global Long-acting PEG-rhG-CSF Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Type in the Global Long-acting PEG-rhG-CSF Market (2025-2031)
  • Table 4.4: Trends of Innovative Drugs in the Global Long-acting PEG-rhG-CSF Market (2019-2024)
  • Table 4.5: Forecast for Innovative Drugs in the Global Long-acting PEG-rhG-CSF Market (2025-2031)
  • Table 4.6: Trends of Generic Drugs in the Global Long-acting PEG-rhG-CSF Market (2019-2024)
  • Table 4.7: Forecast for Generic Drugs in the Global Long-acting PEG-rhG-CSF Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global Long-acting PEG-rhG-CSF Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global Long-acting PEG-rhG-CSF Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Application in the Global Long-acting PEG-rhG-CSF Market (2025-2031)
  • Table 5.4: Trends of Neoplastic Diseases in the Global Long-acting PEG-rhG-CSF Market (2019-2024)
  • Table 5.5: Forecast for Neoplastic Diseases in the Global Long-acting PEG-rhG-CSF Market (2025-2031)
  • Table 5.6: Trends of Blood Disorders in the Global Long-acting PEG-rhG-CSF Market (2019-2024)
  • Table 5.7: Forecast for Blood Disorders in the Global Long-acting PEG-rhG-CSF Market (2025-2031)
  • Table 5.8: Trends of Others in the Global Long-acting PEG-rhG-CSF Market (2019-2024)
  • Table 5.9: Forecast for Others in the Global Long-acting PEG-rhG-CSF Market (2025-2031)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global Long-acting PEG-rhG-CSF Market (2019-2024)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global Long-acting PEG-rhG-CSF Market (2025-2031)
  • Table 7.1: Trends of the North American Long-acting PEG-rhG-CSF Market (2019-2024)
  • Table 7.2: Forecast for the North American Long-acting PEG-rhG-CSF Market (2025-2031)
  • Table 7.3: Market Size and CAGR of Various Type in the North American Long-acting PEG-rhG-CSF Market (2019-2024)
  • Table 7.4: Market Size and CAGR of Various Type in the North American Long-acting PEG-rhG-CSF Market (2025-2031)
  • Table 7.5: Market Size and CAGR of Various Application in the North American Long-acting PEG-rhG-CSF Market (2019-2024)
  • Table 7.6: Market Size and CAGR of Various Application in the North American Long-acting PEG-rhG-CSF Market (2025-2031)
  • Table 7.7: Trends and Forecast for the United States Long-acting PEG-rhG-CSF Market (2019-2031)
  • Table 7.8: Trends and Forecast for the Mexican Long-acting PEG-rhG-CSF Market (2019-2031)
  • Table 7.9: Trends and Forecast for the Canadian Long-acting PEG-rhG-CSF Market (2019-2031)
  • Table 8.1: Trends of the European Long-acting PEG-rhG-CSF Market (2019-2024)
  • Table 8.2: Forecast for the European Long-acting PEG-rhG-CSF Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various Type in the European Long-acting PEG-rhG-CSF Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various Type in the European Long-acting PEG-rhG-CSF Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various Application in the European Long-acting PEG-rhG-CSF Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various Application in the European Long-acting PEG-rhG-CSF Market (2025-2031)
  • Table 8.7: Trends and Forecast for the German Long-acting PEG-rhG-CSF Market (2019-2031)
  • Table 8.8: Trends and Forecast for the French Long-acting PEG-rhG-CSF Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Spanish Long-acting PEG-rhG-CSF Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Italian Long-acting PEG-rhG-CSF Market (2019-2031)
  • Table 8.11: Trends and Forecast for the United Kingdom Long-acting PEG-rhG-CSF Market (2019-2031)
  • Table 9.1: Trends of the APAC Long-acting PEG-rhG-CSF Market (2019-2024)
  • Table 9.2: Forecast for the APAC Long-acting PEG-rhG-CSF Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various Type in the APAC Long-acting PEG-rhG-CSF Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various Type in the APAC Long-acting PEG-rhG-CSF Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various Application in the APAC Long-acting PEG-rhG-CSF Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various Application in the APAC Long-acting PEG-rhG-CSF Market (2025-2031)
  • Table 9.7: Trends and Forecast for the Japanese Long-acting PEG-rhG-CSF Market (2019-2031)
  • Table 9.8: Trends and Forecast for the Indian Long-acting PEG-rhG-CSF Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Chinese Long-acting PEG-rhG-CSF Market (2019-2031)
  • Table 9.10: Trends and Forecast for the South Korean Long-acting PEG-rhG-CSF Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Indonesian Long-acting PEG-rhG-CSF Market (2019-2031)
  • Table 10.1: Trends of the ROW Long-acting PEG-rhG-CSF Market (2019-2024)
  • Table 10.2: Forecast for the ROW Long-acting PEG-rhG-CSF Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various Type in the ROW Long-acting PEG-rhG-CSF Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various Type in the ROW Long-acting PEG-rhG-CSF Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various Application in the ROW Long-acting PEG-rhG-CSF Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various Application in the ROW Long-acting PEG-rhG-CSF Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Middle Eastern Long-acting PEG-rhG-CSF Market (2019-2031)
  • Table 10.8: Trends and Forecast for the South American Long-acting PEG-rhG-CSF Market (2019-2031)
  • Table 10.9: Trends and Forecast for the African Long-acting PEG-rhG-CSF Market (2019-2031)
  • Table 11.1: Product Mapping of Long-acting PEG-rhG-CSF Suppliers Based on Segments
  • Table 11.2: Operational Integration of Long-acting PEG-rhG-CSF Manufacturers
  • Table 11.3: Rankings of Suppliers Based on Long-acting PEG-rhG-CSF Revenue
  • Table 12.1: New Product Launches by Major Long-acting PEG-rhG-CSF Producers (2019-2024)
  • Table 12.2: Certification Acquired by Major Competitor in the Global Long-acting PEG-rhG-CSF Market